Market Overview

3 Biotech Pipeline Areas To Keep An Eye On In 2018


Although there are still a few days left for the year to end, 2017 has turned out to be pretty good for the pharma and biotech sector where FDA approvals are concerned. Till date, the regulatory agency has given its nod to 43 novel drugs, well above the 22 drugs approved last year. Immuno-oncology was a key focus area in 2017, whether it was to do with scientific conferences, clinical trial collaborations, acquisitions or FDA approvals.

The approval of Novartis's NVS Kymriah, a gene cell therapy, and Gilead's GILD Yescarta, a CAR-T (chimeric antigen receptor T cells) cell treatment, ensured that the highly lucrative immuno-oncology market remained in the limelight.

The $11.9 billion acquisition of immuno-oncology focused Kite by Gilead also increased interest in this category with investors expecting more acquisition announcements in this area.

While we see 2017 as a year focused on immuno-oncology, here is a look at three therapeutic areas that we think will garner a lot of interest in 2018.


Immuno-oncology will remain a key focus area in 2018 as well. The basic concept of cancer immunotherapy or immuno-oncology is to utilize certain parts of the immune system to fight the disease. This can be done by stimulating the immune system to attack cancer cells or by introducing immune system components into the body. While some immuno-oncology treatments have the potential to be effective as monotherapies, others may be more effective when combined with other treatments.

Different types of immunotherapies include monoclonal antibodies/mAbs (man-made versions of immune system proteins which can be designed to attack a very specific part of a cancer cell), immune checkpoint inhibitors (recognize and attack cancer cells), vaccines (help prevent or treat cancer) and others that boost the overall immune system.

Encouraging results generated by some companies demonstrating partial and complete responses in late-stage cancer patients and the recent FDA approval of Kymriah and Yescarta has raised hopes for cancer patients and increased interest in this segment of the cancer market. With immuno-oncology set to change the treatment paradigm for cancer, this area represents huge commercial potential.

Companies that have progressed quite a bit in this area include Juno Therapeutics JUNO, Incyte and bluebird bio BLUE with these companies often considered to be acquisition targets.

Alzheimer's Disease

Alzheimer's disease is an area where many companies have tried their luck though not with much success. Over the last several years, big players like Merck, Lilly LLY, Pfizer and J&J have all faced setbacks in their quest to find a treatment for Alzheimer's.

Companies that are currently working on Alzheimer's disease treatments include players like Biogen BIIB, Novartis, AstraZeneca, Eisai and Amgen.

Biogen's aducanumab is one of the most important candidates in the company's pipeline with the candidate currently in a couple of late-stage studies. Biogen is also working on elenbecestat (E2609), a BACE inhibitor in a phase III program and BAN2401, a humanized beta amyloid antibody in phase II development with top-line results expected by the end of January 2018. All three candidates are being developed in collaboration with Eisai.  

Lilly also has quite a few Alzheimer's disease candidates in its pipeline including lanabecestat, which is being developed in collaboration with AstraZeneca with data readout expected in 2019. Meanwhile, Novartis and Amgen are collaborating for BACE1 inhibitor CNP520 which has fast track status in the United Status. Roche is also collaborating with AC Immune for the development of Alzheimer's disease treatments.

Although Alzheimer's has historically been a very challenging therapeutic area with quite a few stocks stumbling in their efforts to find a treatment, the market is highly lucrative. As a result, several companies continue to invest heavily in developing Alzheimer's disease treatments. According to the Alzheimer's Association, in the 10 years from 2002-2012, 244 drugs were tested for Alzheimer's in studies registered with out of which only one succeeded and went on to gain FDA approval.

While these numbers are far from encouraging, success in this area means huge returns considering more than five million Americans are living with Alzheimer's disease with the numbers expected to increase to as much as 16 million by 2050 (Data: Alzheimer's Association). It is considered to be one of the biggest burdens of society and is the sixth leading cause of death across all ages in the United States. The market has immense commercial potential and companies coming out with new treatments could rake in billions of dollars in sales.

Medical Marijuana

Another segment of the pharma and biotech industry that will remain in the limelight next year is the medical marijuana industry. The industry got its first exchange traded fund ("ETF") earlier this year and has been attracting interest from investors over the last few quarters. The industry is expected to grow rapidly with legislators allowing or looking to allow more legal uses of marijuana and marijuana-related products, especially in the medical and life sciences industry.

Some of the key players in this area include GW Pharmaceuticals plc GWPH, INSYS Therapeutics, Corbus Pharmaceuticals Holdings and Zynerba Pharmaceuticals.

GW Pharma commercialized the world's first plant-derived cannabinoid prescription drug, Sativex, which is approved for the treatment of spasticity due to multiple sclerosis. However, the company has been in the news for its lead cannabinoid pipeline candidate, Epidiolex (cannabidiol or CBD), which is in development for a number of rare childhood-onset epilepsy disorders. The company is currently seeking FDA approval for Epidiolex for Dravet syndrome and Lennox-Gastaut syndrome – approval could come as early as mid-2018 if priority review is granted. Epidiolex represents blockbuster potential especially if it is approved across all possible indications. GW Pharma has several new formulations of CBD in development including improved liquid formulations, a solid dose form and an intravenous formulation.

Specialty pharma company, INSYS, uses its proprietary spray technology and capabilities for the development of pharmaceutical cannabinoids for a wide range of indication including treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with significant unmet need. While GW Pharma and INSYS are both Zacks Rank #3 (Hold) stocks, you can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Eli Lilly and Company (NYSE: LLY): Free Stock Analysis Report
Novartis AG (NYSE: NVS): Free Stock Analysis Report
GW Pharmaceuticals PLC (NASDAQ: GWPH): Free Stock Analysis Report
Gilead Sciences, Inc. (NASDAQ: GILD): Free Stock Analysis Report
Biogen Inc. (NASDAQ: BIIB): Free Stock Analysis Report
bluebird bio, Inc. (NASDAQ: BLUE): Free Stock Analysis Report
Juno Therapeutics, Inc. (NASDAQ: JUNO): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research

The preceding article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.

Posted-In: contributor contributorsBiotech News Futures FDA Markets General


Related Articles (BIIB + BLUE)

View Comments and Join the Discussion!

NXT-ID Rallies After Announcing Cryptocurrency Retail Payment Platform

Overstock Further Dives Into Blockchain With Bitt's New Digital Wallet